Patents Assigned to Grunenthal GmbH
  • ABUSE-PROOFED ORAL DOSAGE FORM
    Publication number: 20190142767
    Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 16, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
  • TAMPER-RESISTANT DOSAGE FORM CONTAINING ONE OR MORE PARTICLES
    Publication number: 20190142757
    Abstract: The invention relates to a tamper-resistant pharmaceutical dosage form comprising one or more particles, wherein each of said one or more particles comprises a pharmacologically active ingredient and a physiologically acceptable polymer; has a breaking strength of at least 300 N; has a weight of at least 2 mg; and optionally, comprises a film-coating; wherein the total weight of the pharmaceutical dosage form is greater than the total weight of said one or more particles.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: LUTZ BARNSCHEID, ANJA GEIßLER, KLAUS WENING, JANA PÄTZ
  • NOVEL CRYSTALLINE FORMS
    Publication number: 20190144474
    Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: November 12, 2018
    Publication date: May 16, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: Mazen HANNA, Ning SHAN, David R. WEYNA, Miranda L. CHENEY
  • REINFORCED PHARMACEUTICAL DOSAGE FORM
    Publication number: 20190133956
    Abstract: The invention relates to a reinforced pharmaceutical dosage form comprising a pharmacologically active ingredient and fibers. The reinforced pharmaceutical dosage form is tamper-resistant and thus useful for the avoidance of drug abuse or misuse. The invention also relates to the preparation of such dosage forms and their use in therapy.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 9, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Marcel HAUPTS, Klaus WENING, Carmen STOMBERG, Siegfried EBNER
  • TAMPER-RESISTANT TABLET PROVIDING IMMEDIATE DRUG RELEASE
    Publication number: 20190125680
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of coated particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a physiologically acceptable polymer, preferably a polyalkylene oxide; and form a discontinuous phase within the matrix material; which preferably provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.; and method of using said tablet to treat pain and other conditions.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: Grünenthal GmbH
    Inventors: Sebastian SCHWIER, Marcel HAUPTS, Lutz BARNSCHEID, Jana PÄTZ
  • 6-membered cyclic amines or lactames substituted with urea and phenyl
    Patent number: 10265310
    Abstract: The present invention relates to a compound according to general formula (I) which acts as a modulator of FPR2 and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by FPR2.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 23, 2019
    Assignee: GrÜNENTHAL GMBH
    Inventors: Florian Jakob, Sonja Nordhoff, David Rider, Markus Wagener, Gregor Bahrenberg, Torsten Dunkern
  • TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
    Publication number: 20190111050
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, ANJA GEIßLER- FICHTNER, JANA DENKER, LUTZ BARNSCHEID
  • MODIFIED RELEASE ABUSE DETERRENT DOSAGE FORMS
    Publication number: 20190110992
    Abstract: The invention relates to a pharmaceutical dosage form for oral administration comprising a pharmacologically active compound; wherein a portion of said pharmacologically active compound is contained in a multitude of immediate release particles providing immediate release of the pharmacologically active compound; wherein another portion of said pharmacologically active compound is contained in at least one controlled release particle providing controlled release of the pharmacologically active compound; and wherein the breaking strength of each of the immediate release particles and/or of the at least one controlled release particle is at least 300 N.
    Type: Application
    Filed: October 12, 2018
    Publication date: April 18, 2019
    Applicant: Grünenthal GmbH
    Inventors: Carmen Stomberg, Harald Paul, Klaus Wening, Sebastian Schwier
  • 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
    Publication number: 20190106430
    Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 11, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
  • 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
    Publication number: 20190100497
    Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
    Type: Application
    Filed: December 3, 2018
    Publication date: April 4, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
  • CRYSTALLIZATION METHOD AND BIOAVAILABILITY
    Publication number: 20190083407
    Abstract: Preparation and in vitro and in vivo characterization of novel forms of active pharmaceutical ingredients, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: March 15, 2018
    Publication date: March 21, 2019
    Applicant: GRUNENTHAL GMBH
    Inventor: Mazen HANNA
  • Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
    Publication number: 20190062263
    Abstract: A hitherto unknown crystalline form of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
    Type: Application
    Filed: October 26, 2018
    Publication date: February 28, 2019
    Applicant: Grünenthal GmbH
    Inventors: Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
  • TAMPER-RESISTANT DOSAGE FORM WITH IMMEDIATE RELEASE AND RESISTANCE AGAINST SOLVENT EXTRACTION
    Publication number: 20190054081
    Abstract: A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the pharmaceutical dosage form and/or based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 21, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Anja Geissler-Fichtner, Jana Denker, Lutz Barnscheid
  • Crystallization method and bioavailability
    Patent number: 10195218
    Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: February 5, 2019
    Assignee: GRUNENTHAL GMBH
    Inventor: Mazen Hanna
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20190029976
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIĆ
  • 1,3-DIAZA-SPIRO-[3.4]-OCTANE DERIVATIVES
    Publication number: 20190016685
    Abstract: The invention relates to 1,3-diaza-spiro-[3.4]-octane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 17, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Paul RATCLIFFE, Ingo KONETZKI, Nikolay SITNIKOV, Thomas KOCH, Ruth JOSTOCK
  • COMBINATION OF DRUGS HAVING DIFFERENT POTENCY
    Publication number: 20190015343
    Abstract: The invention relates to a three-dimensionally printed pharmaceutical dosage form comprising a first pharmacologically active ingredient and a second pharmacologically active ingredient; wherein the relative weight ratio of the first pharmacologically active ingredient to the second pharmacologically active ingredient in the pharmaceutical dosage form is within the range of from 10,000:1 to 1:1. The invention also relates to a process for the preparation of such pharmaceutical dosage form by three-dimensional printing, preferably by fused deposition modeling.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 17, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Carmen STOMBERG, Klaus WENING, Marcel HAUPTS
  • FLOATING PHARMACEUTICAL DOSAGE FORM
    Publication number: 20190015344
    Abstract: The invention relates to a pharmaceutical dosage form having a density below the density of gastric fluid, wherein the dosage form comprises a pharmacologically active ingredient and a cavity. The invention also relates to a process for the preparation of said dosage form comprising a three-dimensional printing step.
    Type: Application
    Filed: September 18, 2018
    Publication date: January 17, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Klaus WENING, Carmen STOMBERG, Marcel HAUPTS
  • ABUSE-PROOFED DOSAGE FORM
    Publication number: 20190008849
    Abstract: The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.
    Type: Application
    Filed: July 11, 2018
    Publication date: January 10, 2019
    Applicant: GRÜNENTHAL GMBH
    Inventors: Elisabeth ARKENAU MARIC, Johannes BARTHOLOMAEUS, Heinrich KUGELMANN
  • NOVEL CRYSTALLINE FORMS
    Publication number: 20190002483
    Abstract: Preparation and characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
    Type: Application
    Filed: November 2, 2017
    Publication date: January 3, 2019
    Applicant: GRUNENTHAL GMBH
    Inventors: Mazen HANNA, Ning SHAN, Miranda L. CHENEY, David R. WEYNA, Paul K. ISBESTER, Xufeng SUN